Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 55

1.

Met inhibition revokes IFNγ-induction of PD-1 ligands in MET-amplified tumours.

Martin V, Chiriaco C, Modica C, Acquadro A, Cortese M, Galimi F, Perera T, Gammaitoni L, Aglietta M, Comoglio PM, Vigna E, Sangiolo D.

Br J Cancer. 2019 Mar;120(5):527-536. doi: 10.1038/s41416-018-0315-3. Epub 2019 Feb 6.

2.

Preclinical Antitumor Activity of a Novel Anti-c-KIT Antibody-Drug Conjugate against Mutant and Wild-type c-KIT-Positive Solid Tumors.

Abrams T, Connor A, Fanton C, Cohen SB, Huber T, Miller K, Hong EE, Niu X, Kline J, Ison-Dugenny M, Harris S, Walker D, Krauser K, Galimi F, Wang Z, Ghoddusi M, Mansfield K, Lee-Hoeflich ST, Holash J, Pryer N, Kluwe W, Ettenberg SA, Sellers WR, Lees E, Kwon P, Abraham JA, Schleyer SC.

Clin Cancer Res. 2018 Sep 1;24(17):4297-4308. doi: 10.1158/1078-0432.CCR-17-3795. Epub 2018 May 15.

3.

Selective analysis of cancer-cell intrinsic transcriptional traits defines novel clinically relevant subtypes of colorectal cancer.

Isella C, Brundu F, Bellomo SE, Galimi F, Zanella E, Porporato R, Petti C, Fiori A, Orzan F, Senetta R, Boccaccio C, Ficarra E, Marchionni L, Trusolino L, Medico E, Bertotti A.

Nat Commun. 2017 May 31;8:15107. doi: 10.1038/ncomms15107.

4.

Ruxolitinib therapy and telomere length in myelofibrosis.

Caocci G, Greco M, Delogu G, Secchi C, Perra A, Ghiani S, Orru F, Vacca A, Galimi F, La Nasa G.

Blood Cancer J. 2016 Oct 7;6(10):e479. doi: 10.1038/bcj.2016.91. No abstract available.

5.

Telomere length shortening is associated with treatment-free remission in chronic myeloid leukemia patients.

Caocci G, Greco M, Delogu G, Secchi C, Martino B, Labate C, Abruzzese E, Trawinska MM, Galimberti S, Orru F, Fozza C, Gambacorti Passerini C, Galimi F, La Nasa G.

J Hematol Oncol. 2016 Jul 29;9(1):63. doi: 10.1186/s13045-016-0293-y.

6.

HER2 activating mutations are targets for colorectal cancer treatment.

Kavuri SM, Jain N, Galimi F, Cottino F, Leto SM, Migliardi G, Searleman AC, Shen W, Monsey J, Trusolino L, Jacobs SA, Bertotti A, Bose R.

Cancer Discov. 2015 Aug;5(8):832-41. doi: 10.1158/2159-8290.CD-14-1211.

7.

IGF2 is an actionable target that identifies a distinct subpopulation of colorectal cancer patients with marginal response to anti-EGFR therapies.

Zanella ER, Galimi F, Sassi F, Migliardi G, Cottino F, Leto SM, Lupo B, Erriquez J, Isella C, Comoglio PM, Medico E, Tejpar S, Budinská E, Trusolino L, Bertotti A.

Sci Transl Med. 2015 Jan 28;7(272):272ra12. doi: 10.1126/scitranslmed.3010445.

8.

T cell tyrosine phosphorylation response to transient redox stress.

Secchi C, Carta M, Crescio C, Spano A, Arras M, Caocci G, Galimi F, La Nasa G, Pippia P, Turrini F, Pantaleo A.

Cell Signal. 2015 Apr;27(4):777-88. doi: 10.1016/j.cellsig.2014.12.014. Epub 2015 Jan 6.

PMID:
25572700
9.

Astrocytes contribute to gamma oscillations and recognition memory.

Lee HS, Ghetti A, Pinto-Duarte A, Wang X, Dziewczapolski G, Galimi F, Huitron-Resendiz S, Piña-Crespo JC, Roberts AJ, Verma IM, Sejnowski TJ, Heinemann SF.

Proc Natl Acad Sci U S A. 2014 Aug 12;111(32):E3343-52. doi: 10.1073/pnas.1410893111. Epub 2014 Jul 28.

10.

Anticancer activity of the type I insulin-like growth factor receptor antagonist, ganitumab, in combination with the death receptor 5 agonist, conatumumab.

Tabernero J, Chawla SP, Kindler H, Reckamp K, Chiorean EG, Azad NS, Lockhart AC, Hsu CP, Baker NF, Galimi F, Beltran P, Baselga J.

Target Oncol. 2015 Mar;10(1):65-76. doi: 10.1007/s11523-014-0315-z. Epub 2014 May 11.

11.

Intrinsic resistance to MEK inhibition in KRAS mutant lung and colon cancer through transcriptional induction of ERBB3.

Sun C, Hobor S, Bertotti A, Zecchin D, Huang S, Galimi F, Cottino F, Prahallad A, Grernrum W, Tzani A, Schlicker A, Wessels LF, Smit EF, Thunnissen E, Halonen P, Lieftink C, Beijersbergen RL, Di Nicolantonio F, Bardelli A, Trusolino L, Bernards R.

Cell Rep. 2014 Apr 10;7(1):86-93. doi: 10.1016/j.celrep.2014.02.045. Epub 2014 Mar 27.

12.

TRAIL receptor agonist conatumumab with modified FOLFOX6 plus bevacizumab for first-line treatment of metastatic colorectal cancer: A randomized phase 1b/2 trial.

Fuchs CS, Fakih M, Schwartzberg L, Cohn AL, Yee L, Dreisbach L, Kozloff MF, Hei YJ, Galimi F, Pan Y, Haddad V, Hsu CP, Sabin A, Saltz L.

Cancer. 2013 Dec 15;119(24):4290-8. doi: 10.1002/cncr.28353. Epub 2013 Oct 1.

13.

Amplification of the MET receptor drives resistance to anti-EGFR therapies in colorectal cancer.

Bardelli A, Corso S, Bertotti A, Hobor S, Valtorta E, Siravegna G, Sartore-Bianchi A, Scala E, Cassingena A, Zecchin D, Apicella M, Migliardi G, Galimi F, Lauricella C, Zanon C, Perera T, Veronese S, Corti G, Amatu A, Gambacorta M, Diaz LA Jr, Sausen M, Velculescu VE, Comoglio P, Trusolino L, Di Nicolantonio F, Giordano S, Siena S.

Cancer Discov. 2013 Jun;3(6):658-73. doi: 10.1158/2159-8290.CD-12-0558. Epub 2013 Jun 2.

14.

MACC1 mRNA levels predict cancer recurrence after resection of colorectal cancer liver metastases.

Isella C, Mellano A, Galimi F, Petti C, Capussotti L, De Simone M, Bertotti A, Medico E, Muratore A.

Ann Surg. 2013 Jun;257(6):1089-95. doi: 10.1097/SLA.0b013e31828f96bc.

15.

A randomized, placebo-controlled phase 2 study of ganitumab or conatumumab in combination with FOLFIRI for second-line treatment of mutant KRAS metastatic colorectal cancer.

Cohn AL, Tabernero J, Maurel J, Nowara E, Sastre J, Chuah BY, Kopp MV, Sakaeva DD, Mitchell EP, Dubey S, Suzuki S, Hei YJ, Galimi F, McCaffery I, Pan Y, Loberg R, Cottrell S, Choo SP.

Ann Oncol. 2013 Jul;24(7):1777-85. doi: 10.1093/annonc/mdt057. Epub 2013 Mar 19.

PMID:
23510984
16.

A randomized phase 2 study of paclitaxel and carboplatin with or without conatumumab for first-line treatment of advanced non-small-cell lung cancer.

Paz-Ares L, Bálint B, de Boer RH, van Meerbeeck JP, Wierzbicki R, De Souza P, Galimi F, Haddad V, Sabin T, Hei YJ, Pan Y, Cottrell S, Hsu CP, RamLau R.

J Thorac Oncol. 2013 Mar;8(3):329-37. doi: 10.1097/JTO.0b013e31827ce554.

17.

International, randomized, placebo-controlled, double-blind phase III study of motesanib plus carboplatin/paclitaxel in patients with advanced nonsquamous non-small-cell lung cancer: MONET1.

Scagliotti GV, Vynnychenko I, Park K, Ichinose Y, Kubota K, Blackhall F, Pirker R, Galiulin R, Ciuleanu TE, Sydorenko O, Dediu M, Papai-Szekely Z, Banaclocha NM, McCoy S, Yao B, Hei YJ, Galimi F, Spigel DR.

J Clin Oncol. 2012 Aug 10;30(23):2829-36. doi: 10.1200/JCO.2011.41.4987. Epub 2012 Jul 2.

18.

A randomized, placebo-controlled phase 2 study of ganitumab (AMG 479) or conatumumab (AMG 655) in combination with gemcitabine in patients with metastatic pancreatic cancer.

Kindler HL, Richards DA, Garbo LE, Garon EB, Stephenson JJ Jr, Rocha-Lima CM, Safran H, Chan D, Kocs DM, Galimi F, McGreivy J, Bray SL, Hei Y, Feigal EG, Loh E, Fuchs CS.

Ann Oncol. 2012 Nov;23(11):2834-42. doi: 10.1093/annonc/mds142. Epub 2012 Jun 13.

PMID:
22700995
19.

A molecularly annotated platform of patient-derived xenografts ("xenopatients") identifies HER2 as an effective therapeutic target in cetuximab-resistant colorectal cancer.

Bertotti A, Migliardi G, Galimi F, Sassi F, Torti D, Isella C, Corà D, Di Nicolantonio F, Buscarino M, Petti C, Ribero D, Russolillo N, Muratore A, Massucco P, Pisacane A, Molinaro L, Valtorta E, Sartore-Bianchi A, Risio M, Capussotti L, Gambacorta M, Siena S, Medico E, Sapino A, Marsoni S, Comoglio PM, Bardelli A, Trusolino L.

Cancer Discov. 2011 Nov;1(6):508-23. doi: 10.1158/2159-8290.CD-11-0109. Epub 2011 Sep 2.

20.

Met signaling regulates growth, repopulating potential and basal cell-fate commitment of mammary luminal progenitors: implications for basal-like breast cancer.

Gastaldi S, Sassi F, Accornero P, Torti D, Galimi F, Migliardi G, Molyneux G, Perera T, Comoglio PM, Boccaccio C, Smalley MJ, Bertotti A, Trusolino L.

Oncogene. 2013 Mar 14;32(11):1428-40. doi: 10.1038/onc.2012.154. Epub 2012 May 7.

21.

Microvesicles derived from endothelial progenitor cells enhance neoangiogenesis of human pancreatic islets.

Cantaluppi V, Biancone L, Figliolini F, Beltramo S, Medica D, Deregibus MC, Galimi F, Romagnoli R, Salizzoni M, Tetta C, Segoloni GP, Camussi G.

Cell Transplant. 2012;21(6):1305-20. doi: 10.3727/096368911X627534. Epub 2012 Mar 22.

22.

Inhibition of MEK and PI3K/mTOR suppresses tumor growth but does not cause tumor regression in patient-derived xenografts of RAS-mutant colorectal carcinomas.

Migliardi G, Sassi F, Torti D, Galimi F, Zanella ER, Buscarino M, Ribero D, Muratore A, Massucco P, Pisacane A, Risio M, Capussotti L, Marsoni S, Di Nicolantonio F, Bardelli A, Comoglio PM, Trusolino L, Bertotti A.

Clin Cancer Res. 2012 May 1;18(9):2515-25. doi: 10.1158/1078-0432.CCR-11-2683. Epub 2012 Mar 5.

23.

A preclinical algorithm of soluble surrogate biomarkers that correlate with therapeutic inhibition of the MET oncogene in gastric tumors.

Torti D, Sassi F, Galimi F, Gastaldi S, Perera T, Comoglio PM, Trusolino L, Bertotti A.

Int J Cancer. 2012 Mar 15;130(6):1357-66. doi: 10.1002/ijc.26137. Epub 2011 May 30.

24.

Genetic and expression analysis of MET, MACC1, and HGF in metastatic colorectal cancer: response to met inhibition in patient xenografts and pathologic correlations.

Galimi F, Torti D, Sassi F, Isella C, Corà D, Gastaldi S, Ribero D, Muratore A, Massucco P, Siatis D, Paraluppi G, Gonella F, Maione F, Pisacane A, David E, Torchio B, Risio M, Salizzoni M, Capussotti L, Perera T, Medico E, Di Renzo MF, Comoglio PM, Trusolino L, Bertotti A.

Clin Cancer Res. 2011 May 15;17(10):3146-56. doi: 10.1158/1078-0432.CCR-10-3377. Epub 2011 Mar 29.

25.

Molecular analysis of Fanconi anemia and mismatch repair genes in patients with colorectal carcinoma.

Colombino M, Avallone A, Izzo F, Tatangelo F, Budroni M, Cossu A, Galimi F, Comella P, Botti G, Sini MC, Tanda F, Palmieri G; Southern Italy Cooperative Oncology Group.

Oncol Rep. 2011 Apr;25(4):899-904. doi: 10.3892/or.2011.1169. Epub 2011 Jan 31.

PMID:
21286667
26.

Inhibition of Src impairs the growth of met-addicted gastric tumors.

Bertotti A, Bracco C, Girolami F, Torti D, Gastaldi S, Galimi F, Medico E, Elvin P, Comoglio PM, Trusolino L.

Clin Cancer Res. 2010 Aug 1;16(15):3933-43. doi: 10.1158/1078-0432.CCR-10-0106. Epub 2010 Jul 13.

27.
28.

Only a subset of Met-activated pathways are required to sustain oncogene addiction.

Bertotti A, Burbridge MF, Gastaldi S, Galimi F, Torti D, Medico E, Giordano S, Corso S, Rolland-Valognes G, Lockhart BP, Hickman JA, Comoglio PM, Trusolino L.

Sci Signal. 2009;2(102):er11.

PMID:
20039471
29.

Only a subset of Met-activated pathways are required to sustain oncogene addiction.

Bertotti A, Burbridge MF, Gastaldi S, Galimi F, Torti D, Medico E, Giordano S, Corso S, Rolland-Valognes G, Lockhart BP, Hickman JA, Comoglio PM, Trusolino L.

Sci Signal. 2009 Dec 8;2(100):ra80. doi: 10.1126/scisignal.2000643. Erratum in: Sci Signal. 2009 Dec 22;2(102):er11. Corrected and republished in: Sci Signal. 2009;2(102):er11.

30.

In vivo manipulation of gene expression in non-human primates using lentiviral vectors as delivery vehicles.

Dissen GA, Lomniczi A, Neff TL, Hobbs TR, Kohama SG, Kroenke CD, Galimi F, Ojeda SR.

Methods. 2009 Sep;49(1):70-7. doi: 10.1016/j.ymeth.2009.06.004. Epub 2009 Jun 24. Review.

31.

Macrophage stimulating protein may promote tubular regeneration after acute injury.

Cantaluppi V, Biancone L, Romanazzi GM, Figliolini F, Beltramo S, Galimi F, Camboni MG, Deriu E, Conaldi P, Bottelli A, Orlandi V, Herrera MB, Pacitti A, Segoloni GP, Camussi G.

J Am Soc Nephrol. 2008 Oct;19(10):1904-18. doi: 10.1681/ASN.2007111209. Epub 2008 Jul 9.

32.

Enhanced at puberty 1 (EAP1) is a new transcriptional regulator of the female neuroendocrine reproductive axis.

Heger S, Mastronardi C, Dissen GA, Lomniczi A, Cabrera R, Roth CL, Jung H, Galimi F, Sippell W, Ojeda SR.

J Clin Invest. 2007 Aug;117(8):2145-54.

33.

Creating prodynorphin-expressing stem cells alerted for a high-throughput of cardiogenic commitment.

Maioli M, Asara Y, Pintus A, Ninniri S, Bettuzzi S, Scaltriti M, Galimi F, Ventura C.

Regen Med. 2007 Mar;2(2):193-202.

34.

Fxna, a novel gene differentially expressed in the rat ovary at the time of folliculogenesis, is required for normal ovarian histogenesis.

Garcia-Rudaz C, Luna F, Tapia V, Kerr B, Colgin L, Galimi F, Dissen GA, Rawlings ND, Ojeda SR.

Development. 2007 Mar;134(5):945-57. Epub 2007 Jan 31.

35.

Saturated fatty acids inhibit induction of insulin gene transcription by JNK-mediated phosphorylation of insulin-receptor substrates.

Solinas G, Naugler W, Galimi F, Lee MS, Karin M.

Proc Natl Acad Sci U S A. 2006 Oct 31;103(44):16454-9. Epub 2006 Oct 18.

36.

Antiangiogenic and immunomodulatory effects of rapamycin on islet endothelium: relevance for islet transplantation.

Cantaluppi V, Biancone L, Romanazzi GM, Figliolini F, Beltramo S, Ninniri MS, Galimi F, Romagnoli R, Franchello A, Salizzoni M, Perin PC, Ricordi C, Segoloni GP, Camussi G.

Am J Transplant. 2006 Nov;6(11):2601-11. Epub 2006 Sep 18.

37.

Fate of endogenous stem/progenitor cells following spinal cord injury.

Horky LL, Galimi F, Gage FH, Horner PJ.

J Comp Neurol. 2006 Oct 1;498(4):525-38.

38.

Forced retinoic acid receptor alpha homodimers prime mice for APL-like leukemia.

Sternsdorf T, Phan VT, Maunakea ML, Ocampo CB, Sohal J, Silletto A, Galimi F, Le Beau MM, Evans RM, Kogan SC.

Cancer Cell. 2006 Feb;9(2):81-94.

39.

Development of ecdysone-regulated lentiviral vectors.

Galimi F, Saez E, Gall J, Hoong N, Cho G, Evans RM, Verma IM.

Mol Ther. 2005 Jan;11(1):142-8.

40.

A role for bone marrow-derived cells in the vasculature of noninjured CNS.

Galimi F, Summers RG, van Praag H, Verma IM, Gage FH.

Blood. 2005 Mar 15;105(6):2400-2. Epub 2004 Nov 30.

PMID:
15572598
41.

CRE recombinase-inducible RNA interference mediated by lentiviral vectors.

Tiscornia G, Tergaonkar V, Galimi F, Verma IM.

Proc Natl Acad Sci U S A. 2004 May 11;101(19):7347-51. Epub 2004 Apr 30.

42.

CREB controls hepatic lipid metabolism through nuclear hormone receptor PPAR-gamma.

Herzig S, Hedrick S, Morantte I, Koo SH, Galimi F, Montminy M.

Nature. 2003 Nov 13;426(6963):190-3.

PMID:
14614508
43.

Reversal of human cellular senescence: roles of the p53 and p16 pathways.

Beauséjour CM, Krtolica A, Galimi F, Narita M, Lowe SW, Yaswen P, Campisi J.

EMBO J. 2003 Aug 15;22(16):4212-22.

44.

Two mechanisms for human immunodeficiency virus type 1 inhibition by N-terminal modifications of RANTES.

Pastore C, Picchio GR, Galimi F, Fish R, Hartley O, Offord RE, Mosier DE.

Antimicrob Agents Chemother. 2003 Feb;47(2):509-17.

45.

Gene therapy of Fanconi anemia: preclinical efficacy using lentiviral vectors.

Galimi F, Noll M, Kanazawa Y, Lax T, Chen C, Grompe M, Verma IM.

Blood. 2002 Oct 15;100(8):2732-6.

PMID:
12351379
46.

Opportunities for the use of lentiviral vectors in human gene therapy.

Galimi F, Verma IM.

Curr Top Microbiol Immunol. 2002;261:245-54. Review. No abstract available.

PMID:
11892251
47.

Hepatocyte growth factor is a regulator of monocyte-macrophage function.

Galimi F, Cottone E, Vigna E, Arena N, Boccaccio C, Giordano S, Naldini L, Comoglio PM.

J Immunol. 2001 Jan 15;166(2):1241-7.

48.

Hepatocyte growth factor is a coupling factor for osteoclasts and osteoblasts in vitro.

Grano M, Galimi F, Zambonin G, Colucci S, Cottone E, Zallone AZ, Comoglio PM.

Proc Natl Acad Sci U S A. 1996 Jul 23;93(15):7644-8.

49.

The HIV-1 nef protein interferes with phosphatidylinositol 3-kinase activation 1.

Graziani A, Galimi F, Medico E, Cottone E, Gramaglia D, Boccaccio C, Comoglio PM.

J Biol Chem. 1996 Mar 22;271(12):6590-3.

50.

Biological activation of pro-HGF (hepatocyte growth factor) by urokinase is controlled by a stoichiometric reaction.

Naldini L, Vigna E, Bardelli A, Follenzi A, Galimi F, Comoglio PM.

J Biol Chem. 1995 Jan 13;270(2):603-11.

Supplemental Content

Loading ...
Support Center